Lipopharma is a pioneering clinical-stage biopharmaceutical company that focuses its activities on the discovery, rational design and clinical development of a new generation of medicines that act through the selective regulation of membrane lipids, a novel therapeutic strategy known as “Membrane Lipid Therapy” (MLT). Lipopharma arose as an academic spin-off, founded to turn new scientific breakthroughs and discoveries made by scientists at the Institute of Health Science Research (IUNICS - part of the University of the Balearic Islands in Mallorca, Spain) into a new class of innovative lipid regulator therapeutic agents that we believe have dramatic game-changing potential in the treatment of life-threatening conditions like cancer, CNS, inflammatory or metabolic diseases
Lipopharma announces at Biotrinity 2013 the initiation of the first clinical study in cancer with Minerval
Palma de Mallorca, May 15th 2013. Lipopharma presented yesterday its cancer program with Minerval at Biotrinity 2013 and announced the start of the first oncology clinical study with this novel lipid regulator.
After obtaining all required regulatory authorizations in the UK for the clinical study MIN-001-1203, Lipopharma confirmed the activation of the first site in Sutton, Surrey (UK), which will be recruiting participants from today. The other two sites taking part in the first part of the study (in Newcastle and Barcelona) are expected to be also active from the first week of June. The hospital in Zurich will be joining the study in the second phase of the trial, once the dose escalation phase is completed. Up to 50 patients with advanced solid tumors, including malignant glioma, are expected to be enrolled in this clinical trial.